How deadly is Prostate cancer?

Lalela leli khasi

Umdlavuza we-prostate uyabulala kangakanani?

Umdlavuza we-prostate uwumdlavuza wesibili ovame kakhulu emadodeni emhlabeni wonke, kanti kulinganiselwa ukuthi kunamacala amasha angu-1,276 million abikiwe ngo-2018, amelela u-7.1% wawo wonke amacala omdlavuza emadodeni.

Izinga lokufa ngenxa yomdlavuza we-prostate nalo liphakeme, futhi kulinganiselwa ukuthi kwafa abantu abangu-37,005 emhlabeni wonke ngo-2018.

Nokho, izinga lokufa liyahlukahluka kakhulu kuye ngesifunda, iNtshonalanga Afrika inengozi yesihlanu ephezulu yokufa ngenxa yomdlavuza we-prostate emhlabeni, kanti iNigeria inabantu abaningi nomnotho omkhulu kunayo yonke kule ndawo.

ENigeria, umdlavuza we-prostate uwumdlavuza ovame kakhulu futhi obulala kakhulu emadodeni, okulinganiselwa ukuthi unamacala angu-32.8 nokufa okungama-16.3 emadodeni ayizinkulungwane eziyikhulu.

Lokhu kungaphezu kokuphindwe kabili kwezinga lokufa eNyakatho Melika.

Ukuthola lesi sifo sekwephuzile, izinsiza ezilinganiselwe zokuhlola nokuthola, kanye nokwehla kwemibhalo nokubikwa kwamacala kunomthelela ezingeni eliphakeme lokufa eNigeria.

E-United States, umdlavuza we-prostate uyimbangela yesibili evame kakhulu yokufa ngenxa yomdlavuza emadodeni, futhi cishe amadoda angu-40,000 ayafa yilesi sifo unyaka ngamunye.

Izinga lokufa ngenxa yomdlavuza we-prostate belilokhu lincipha kancane kusukela ekuqaleni kwawo-1990, kodwa lisalokhu liyinkinga enkulu yezempilo.

Sekukonke, umdlavuza we-prostate uyisifo esibulalayo, ikakhulukazi ezifundeni ezinokufinyelela okulinganiselwe ekunakekelweni kwezokwelapha nasezinsizakalweni zokuhlola.

Nokho, ukutholakala nokwelashwa kusenesikhathi kungathuthukisa kakhulu imiphumela futhi kunciphise izinga lokufa.

Izikhombo

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Nakata S, Takahashi H, Ohtake N, Takei T, Yamanaka H: Trends and characteristics in prostate cancer mortality in Japan. Int J Urol. 2000, 7 (7): 254-7.

Pishgar F, Ebrahimi H, Saeedi Moghaddam S, Fitzmaurice C, Amini E: Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the Global Burden of Disease Study 2015. J Urol. 2018, 199 (5): 1224-1232.

Cai Q, Chen Y, Zhang D, Pan J, Xie Z, Xu C, Li S, Zhang X, Gao Y, Hou J, Guo X, Zhou X, Zhang B, Ma F, Zhang W, Lin G, Xin Z, Niu Y, Wang Y: Estimates of over-time trends in incidence and mortality of prostate cancer from 1990 to 2030. Transl Androl Urol. 2020, 9 (2): 196-209.

Feletto E, Bang A, Cole-Clark D, Chalasani V, Rasiah K, Smith DP: An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high? World J Urol. 2015, 33 (11): 1677-87.

Taksler GB, Keating NL, Cutler DM: Explaining racial differences in prostate cancer mortality. Cancer. 2012, 118 (17): 4280-9.

Ukuzikhulula: kwezokwelapha

Le webhusayithi inikezwa ngezinjongo zemfundo nezokwaziswa kuphela futhi ayifaki ukunikeza izeluleko zezokwelapha noma izinsizakalo zobungcweti.

Imininingwane enikeziwe akufanele isetshenziselwe ukuxilonga noma ukwelapha inkinga noma isifo, futhi labo abafuna iseluleko somuntu siqu sezokwelapha kufanele babonane nodokotela onelayisense.

Sicela uqaphele ukuthi inethiwekhi ye-neural ekhiqiza izimpendulo zemibuzo, ayinembile ngokukhethekile uma kuziwa kokuqukethwe kwezinombolo. Ngokwesibonelo, inani labantu abanesifo esithile.

Ngaso sonke isikhathi funa iseluleko sikadokotela wakho noma omunye umhlinzeki wezempilo ofanelekayo mayelana nesimo sezokwelapha. Ungalokothi ungayinaki iseluleko sezokwelapha sobungcweti noma ubambezele ukusifuna ngenxa yento oyifundile kule webhusayithi. Uma ucabanga ukuthi ungase ube nesimo esiphuthumayo sezokwelapha, shayela i-911 noma uye egumbini lezimo eziphuthumayo eliseduze ngokushesha. Ayikho ubudlelwano bokuthi udokotela-isiguli obakhiwe yile webhusayithi noma ukusetshenziswa kwayo. I-BioMedLib noma abasebenzi bayo, noma noma yimuphi umnikeli wale webhusayithi, akenzi noma yimiphi imibono, ecacile noma ecacile, mayelana nolwazi olunikezwe lapha noma ukusetshenziswa kwayo.

Ukuzikhulula: amalungelo obunikazi

I-Digital Millennium Copyright Act ka-1998, i-17 U.S.C. § 512 (i- DMCA) inikeza indlela yokuphendula kubanikazi bamalungelo obunikazi abakholelwa ukuthi okokusebenza okubonakala kwi-Internet kwephula amalungelo abo ngaphansi komthetho we-copyright wase-US.

Uma ukholelwa ngobuqotho ukuthi noma yikuphi okuqukethwe noma okokusebenza okwenziwe kutholakale maqondana newebhusayithi yethu noma izinsizakalo kwephula ilungelo lakho lobunikazi, wena (noma umenzeli wakho) ungasithumela isaziso esicela ukuthi okuqukethwe noma okokusebenza kususwe, noma ukufinyelela kukho kuvinjelwe.

Izaziso kufanele zithunyelwe ngokubhala nge-imeyili (bheka isigaba esithi "Contact" ukuze uthole ikheli le-imeyili).

I-DMCA idinga ukuthi isaziso sakho sokwephulwa kwamalungelo obunikazi kubandakanye imininingwane elandelayo: (1) incazelo yomsebenzi onamalungelo obunikazi oyisihloko sokwephulwa okusolwa; (2) incazelo yokuqukethwe okusolwa ukwephula amalungelo obunikazi nolwazi olwanele ukusivumela ukuthi sithole okuqukethwe; (3) imininingwane yokuxhumana nawe, kufaka phakathi ikheli lakho, inombolo yocingo nekheli le-imeyili; (4) isitatimende sakho sokuthi unokholo oluhle lokuthi okuqukethwe ngendlela ekhonjiwe ngayo akugunyaziwe ngumnikazi wamalungelo obunikazi, noma umenzeli wakhe, noma ngokusebenza kwanoma imuphi umthetho;

(5) isitatimende sakho, esisayinwe ngaphansi kwesijeziso sokufakaza amanga, sokuthi ukwaziswa okusesazisweni kunembile nokuthi unegunya lokuphoqelela amalungelo obunikazi okuthiwa aphuliwe;

futhi (6) isignesha ebonakalayo noma ye-elekthronikhi yomnikazi we-copyright noma umuntu ogunyaziwe ukuba asebenze egameni lomnikazi we-copyright.

Ukwehluleka ukufaka yonke imininingwane engenhla kungaholela ekubambezelweni kokucutshungulwa kwesikhalazo sakho.

Othintana naye

Sicela usithumelele i-imeyili nganoma yimiphi imibuzo / iziphakamiso.

How deadly is prostate cancer?

Prostate cancer is the second most common cancer in men worldwide, with an estimated 1.276 million new cases reported in 2018, representing 7.1% of all cancer cases in men.

The mortality rate for prostate cancer is also high, with an estimated 37,005 deaths worldwide in 2018.

However, the mortality rate varies greatly by region, with Western Africa having the fifth-highest risk for prostate cancer mortality in the world, and Nigeria having the largest population and economy in this region.

In Nigeria, prostate cancer is both the most common and most deadly cancer for men, with an estimated 32.8 cases and 16.3 deaths per 100,000 men.

This is more than double the death rate in North America.

Late detection of the disease, limited resources for screening and detection, and decreased documentation and reporting of cases contribute to the high mortality rate in Nigeria.

In the United States, prostate cancer is the second most common cause of cancer death in men, with approximately 40,0000 men dying from the disease each year.

The prostate cancer death rate has been slowly decreasing since the early 1990s, but it remains a significant health concern.

Overall, prostate cancer is a deadly disease, particularly in regions with limited access to medical care and screening resources.

However, early detection and treatment can significantly improve outcomes and reduce mortality rates.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.